A Phase II randomized study to evaluate the immunologic and antitumor activity of concurrent VRP-HER2 vaccination and Pembrolizumab for patients with advanced HER2-overexpressing breast cancer
Administered By
Awarded By
Contributors
- Force, Jeremy M Principal Investigator
Start/End
- July 11, 2018 - April 30, 2022